The Effects of Positive Expiratory Pressure Breathing on The Rate of Post-exercise Recovery in Patients With COPD
NCT ID: NCT02398071
Last Updated: 2015-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2014-08-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Post-exercise breathing with PEP device will increase the rate of recovery more than breathing without PEP device.
2. Post-exercise breathing with PEP device will not create harmful effects on cardiopulmonary function in COPD patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oxidative Stress and Endothelial Dysfunction in Obstructive Sleep Apnea
NCT00646971
PAP Therapy Sleep Apnea and Exercise
NCT01786291
Evaluating an Under-mattress Sleep Monitor Compared to a Peripheral Arterial Tonometry Device in the Diagnosis of Obstructive Sleep Apnea
NCT04778748
Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease
NCT00738179
The Influences of Intervention With Home-based Recovery Activity in Obstructive Sleep Apnea Syndrome
NCT02278094
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The pathophysiological hallmark of COPD is an expiratory air flow limitation. During exercise, increasing ventilatory demands can induce premature airway closure by forced expiration leading to air trapping and further leading to lung hyperinflation. Dynamic hyperinflation (DH) during exercise contributes to increased end expiratory lung volume (EELV), reduces inspiratory capacity (IC), and increases the mechanical load on inspiratory muscles leading to dyspnea, exercise intolerance, limited physical activity, and thus to a poor quality of life in COPD patients. In addition, abnormal lung mechanical function during dynamic hyperinflation leads to increased sensation of dyspnea, which is the disparity between respiratory drive and the respiratory mechanical response. Abnormal controls of blood chemicals and of vasculature factors also aggravate the sensation of dyspnea.
The autonomic dysfunction (AD) that occurs in the patients with COPD is evident as an inability of heart rate to reach an appropriate level during exercise (chronotropic incompetence; CI). There is also a prolonged heart rate recovery (HRR) at the end of exercise which may contribute to increase dyspnea sensations and increased mortality rate in COPD.
Expiratory flow retardation when breathing with a positive expiratory pressure (PEP) device is the one of various techniques to manage dyspnea in COPD. Most studies using a PEP device have focused on investigating the effects of PEP to reduce lung hyperinflation, reduce dyspnea, and increase exercise capacity. Only one study of Martin and Devenport, has examined the effects of PEP breathing during the recovery periods after exercise and found that following 6 minutes sub-maximal treadmill walking, 6 breath exhalation against a 10 cmH2O threshold PEP reduced dyspnea and increased HRR. Oxygen pulse saturation (SpO2) was also increased within 2 minutes although there was no statistical significant between groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PEP interventon
Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 5 cmH2O
A water pressure threshold device (BreatheMAX)
BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
Sham intervention
Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 0 cmH2O
A water pressure threshold device (BreatheMAX)
BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
A water pressure threshold device (BreatheMAX)
BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Free of exacerbations for more than 4 weeks (as defined by a change to pharmacological therapy, admission to hospital or ER or unscheduled clinic visit)
* Age between 40-70 years old
* Good communication
Exclusion Criteria
* Cardiovascular disease
* Neurological or psychiatric illness
* Any other comorbidities which would affect ability to undertake exercise test
40 Years
70 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Khajonsak Pongpanit
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Khajonsak Pongpanit
Graduate School, Khon Kaen university
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chulee Jones, PhD
Role: STUDY_DIRECTOR
School of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University, Thailand
Watchara Boonsawat, PhD
Role: STUDY_CHAIR
Department of medicine, Faculty of medicine, Khon Kaen university, Thailand
David A. Jones, PhD
Role: STUDY_CHAIR
School of Healthcare Science, Faculty of Science and Engineering, Manchester Metropolitan University, United Kingdom
Khajonsak Pongpanit, MSc student
Role: PRINCIPAL_INVESTIGATOR
School of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University, Thailand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
School of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University
Khon Kaen, Muang Khon Kaen, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Khon Kaen University
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.